Predictive Oncology Inc (POAI)
1.435
-0.32
(-18.47%)
USD |
NASDAQ |
May 31, 16:00
1.43
0.00 (0.00%)
After-Hours: 20:00
Predictive Oncology SG&A Expense (Annual): 10.94M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.94M |
| December 31, 2022 | 12.47M |
| December 31, 2021 | 11.71M |
| December 31, 2020 | 10.94M |
| December 31, 2019 | 11.69M |
| December 31, 2018 | 6.996M |
| December 31, 2017 | 5.146M |
| December 31, 2016 | 6.801M |
| Date | Value |
|---|---|
| December 31, 2015 | 3.903M |
| December 31, 2014 | 7.034M |
| December 31, 2013 | 9.206M |
| December 31, 2012 | 7.220M |
| December 31, 2011 | 4.146M |
| December 31, 2010 | 2.351M |
| December 31, 2009 | 2.005M |
| December 31, 2008 | 1.352M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
10.94M
Minimum
2020
12.47M
Maximum
2022
11.55M
Average
11.69M
Median
2019
SG&A Expense (Annual) Benchmarks
| icad Inc | 17.06M |
| Perspective Therapeutics Inc | 21.06M |
| Semler Scientific Inc | 32.44M |
| Xtant Medical Holdings Inc | 64.29M |
| Asensus Surgical Inc | 36.08M |